Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Øystein Soug
Person

Øystein Soug

Tracked across 2 events · 13 articles · First seen Jun 18, 2026 · Last active Aug 11, 2026

Sentiment
35
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 60
Tech
Oncoinvent Radspherin Phase 2 Milestone
Impact: Øystein Soug, CEO of Oncoinvent, commented on the significance of the recruitment milestone, highlighting the company's commitment and the potential of Radspherin.
Jun 18, 2026 · 7 articles
2 10
Tech
Oncoinvent publishes Radspherin dosimetry results
Oncoinvent, a biotech company developing Radspherin, an alpha radiopharmaceutical for treating peritoneal metastases, announced the publication of clinical dosimetry data in the The Journal of Nuclear Medicine. The publication, titled 'Normal Tissue Dosimetry of Intraperitoneal…
Impact: Øystein Soug is the CEO of Oncoinvent and is listed as a contact. His role is administrative in this context.
Aug 11, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Øystein Soug live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.